Ask an Expert is a free question-and-answer service about breast cancer and breast health that is available on weekends. If you'd like to ask a question or comment, please visit us again on Saturday or Sunday. In the meantime, please search the existing topics using the search tool at the top of the page. It's quite possible that one of our many existing topics already addresses your question.
If you would like a consultation with a breast specialist at the Johns Hopkins Avon Foundation Breast Center, call 443-778-2778. It is possible to get an appointment for a second opinion within a few days of contacting us.
We hope you find the information helpful!
| Forum | Questions | Ask a Question | |
|---|---|---|---|
 |
LCIS - Lobular Carcinoma In Situ Questions about lobular carcinoma in situ. |
140 |  |
| Asked | Publicly Submitted Question | ||
|---|---|---|---|
| 6/9/2011 | I read all the other entries before emailing you as I am trying to learn as much as I can, however, I believe I have a unique situation. I received final diagnosis of "LCIS with no invasive carcinoma identified" today. Right breast only.(I had genetic testing...came back negative for any BC gene.)The doctor's office is setting me up with an oncologist in their practice to be followed closely...however, I am on warfarin for Factor V Leiden Resistance to Activated Protein C and cannot take tamoxifen which can cause blood clots. I understand it is usually prescribed for someone with LCIS. So, my question is, what would be my other options? And are there any other drugs out there that do not cause blood clots? Thank you so much for your time. | ||
| Replied | JHU's Breast Center Reply | ||
| 6/9/2011 | Thank you for turning to the Johns Hopkins Breast center with your questions. Although the name includes the term carcinoma, lobular carcinoma in situ (LCIS) is not really cancer, but rather a noninvasive condition that increases the risk of developing cancer in the future. about 25 percent of patients who have LCIS will develop breast cancer at some point in their lifetime. This increased risk applies to both breasts, regardless of which breast is affected with LCIS. Treating lobular carcinoma in situ (LCIS) can be complicated because the condition itself is not cancerous and the majority of people with LCIS do not ever develop cancer; yet, it is known that they have a higher risk of developing cancer in the future. With LCIS, you should increase breast surveillance, my consider raloxifene rather than tamoxifen, and in some cases women consider mastectomy. Seek a consultation at a Comprehensive Breast center where you will be examined and evaluated by breast experts. Best wishes! | ||
Please note: This service is not intended to provide primary medical advice concerning specific medical care or treatment. Ask an Expert is a free service operated by health care professionals at the Johns Hopkins Avon Foundation Breast Center. Due to the volume of questions and their complexity, there are times when medical oncologists, surgeons, radiation oncologists or oncology nurses are consulted for their input. These individuals volunteer their time for this service and will respond as soon as they are able. Please do not post or send the same question to us in multiple locations or categories.